These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 25962092

  • 1. AACE/ACE disease state clinical review: diagnosis and management of midgut carcinoids.
    Liu EH, Solorzano CC, Katznelson L, Vinik AI, Wong R, Randolph G.
    Endocr Pract; 2015 May; 21(5):534-545. PubMed ID: 25962092
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors.
    Ricci S, Antonuzzo A, Galli L, Orlandini C, Ferdeghini M, Boni G, Roncella M, Mosca F, Conte PF.
    Am J Clin Oncol; 2000 Aug; 23(4):412-5. PubMed ID: 10955874
    [Abstract] [Full Text] [Related]

  • 5. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.
    O'Toole D, Ducreux M, Bommelaer G, Wemeau JL, Bouché O, Catus F, Blumberg J, Ruszniewski P.
    Cancer; 2000 Feb 15; 88(4):770-6. PubMed ID: 10679645
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
    Fisher GA, Wolin EM, Liyanage N, Lowenthal SP, Mirakhur B, Pommier RF, Shaheen M, Vinik AI, ELECT Study Investigators.
    Endocr Pract; 2018 Mar 15; 24(3):243-255. PubMed ID: 29547049
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Management of Diarrhea in Patients With Carcinoid Syndrome.
    Naraev BG, Halland M, Halperin DM, Purvis AJ, OʼDorisio TM, Halfdanarson TR.
    Pancreas; 2019 Sep 15; 48(8):961-972. PubMed ID: 31425482
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
    Phan AT, Kunz PL, Reidy-Lagunes DL.
    Clin Adv Hematol Oncol; 2015 May 15; 13(5 Suppl 5):1-18; quiz 1 p following 18. PubMed ID: 26430956
    [Abstract] [Full Text] [Related]

  • 19. Developments in diagnosis and treatment of metastatic midgut carcinoid tumors. A review.
    Taal BG, Smits M.
    Minerva Gastroenterol Dietol; 2005 Dec 15; 51(4):335-44. PubMed ID: 16282961
    [Abstract] [Full Text] [Related]

  • 20. An update of lanreotide acetate for treatment of adults with carcinoid syndrome.
    Guadalupe E, Deshpande HA, Stein SM.
    Drugs Today (Barc); 2018 Aug 15; 54(8):457-465. PubMed ID: 30209440
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.